雷替曲塞联合奥沙利铂二线治疗晚期胃癌的临床效果分析

Clinical Effect Analysis of Raltitrexed and Oxaliplatin as Second-Line Treatment of Advanced Gastric Cancer

目的:探讨雷替曲塞联合奥沙利铂二线治疗晚期胃癌的临床效果。方法:选取2021年3月-2023年2月滨州市博兴县人民医院收治的一线治疗失败的晚期胃癌患者73例作为研究对象,根据随机数字表法分为参照组(n=36)、试验组(n=37)。参照组应用雷替曲塞治疗,试验组在参照组基础上应用奥沙利铂治疗。比较两组临床疗效、不良反应及生活质量。结果:试验组治疗总有效率高于参照组,差异有统计学意义(P=0.022)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。治疗前,两组一般健康状况、社会功能、生理机能、情感职能、生理职能、精神健康、精力、躯体疼痛评分比较,差异无统计学意义(P>0.05);治疗后,两组一般健康状况、社会功能、生理机能、情感职能、生理职能、精神健康、精力、躯体疼痛评分高于治疗前,且试验组高于参照组,差异有统计学意义(P<0.05)。结论:雷替曲塞联合奥沙利铂二线治疗晚期胃癌的临床效果较好,有助于提高患者生活质量,且安全性较高。

Objective:To explore the clinical effect of raltitrexed combined with oxaliplatin as second-line treatment of advanced gastric cancer.Methods:A total of 73 patients with advanced gastric cancer patients who failed first-line treatment and were admitted to Boxing People's Hospital from March 2021 to February 2023 were selected as the study subjects.They were divided into reference group(n=36)and experimental group(n=37)by random number table method.The reference group was treated with raltitrexed,and the experimental group was treated with oxaliplatin on the basis of the reference group.The clinical efficacy,adverse reactions and quality of life in the two groups were compared.Results:The total effective rate of treatment in the experimental group was higher than that in the reference group,and the difference was statistically significant(P=0.022).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Before treatment,there was no significant difference in the scores of general health,social function,physiological function,emotional function,physiological functioning,mental health,vitality and physical pain between the two groups(P>0.05).After treatment,the scores of general health,social function,physiological function,emotional function,physiological functioning,mental health,vitality and physical pain in the two groups were higher than those before treatment,the scores in the experimental group were higher than those in the reference group,and the difference was statistically significant(P<0.05).Conclusion:The combination of raltitrexed and oxaliplatin as the second-line treatment of advanced gastric cancer has better clinical effects,helps to improve the quality of life of patients,and has a high safety.